×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
复旦大学上海医学院 [11]
中国医学科学院 北... [10]
吉林大学白求恩第一医... [7]
昆明医科大学 [6]
南华大学 [3]
西安交通大学 [2]
更多...
内容类型
期刊论文 [34]
会议论文 [8]
发表日期
2019 [2]
2018 [7]
2017 [1]
2016 [8]
2014 [8]
2013 [1]
更多...
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共42条,第1-10条
帮助
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
发表日期升序
发表日期降序
作者升序
作者降序
提交时间升序
提交时间降序
题名升序
题名降序
CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial
期刊论文
CANCER COMMUNICATIONS, 2019, 卷号: 39
作者:
Shi, Yuankai
;
Li, Jin
;
Xu, Jianming
;
Sun, Yan
;
Wang, Liwei
收藏
  |  
浏览/下载:115/0
  |  
提交时间:2019/12/05
CMAB009
Cetuximab
Irinotecan
Second-line
mCRC
EGFR
KRAS
Immunogenicity
Fluoropyrimidine
Oxaliplatin failure
CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase I
期刊论文
2019, 卷号: 39, 期号: 1, 页码: 28
作者:
Shi, Yuankai
;
Li, Jin
;
Xu, Jianming
;
Sun, Yan
;
Wang, Liwei
收藏
  |  
浏览/下载:45/0
  |  
提交时间:2020/01/03
CMAB009
Cetuximab
Irinotecan
Second-line
mCRC
EGFR
KRAS
Immunogenicity
Fluoropyrimidine
Oxaliplatin failure
Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial
期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2018, 卷号: 36, 期号: 30
作者:
Qin, Shukui
;
Li, Jin
;
Wang, Liwei
;
Xu, Jianming
;
Cheng, Ying
收藏
  |  
浏览/下载:5/0
  |  
提交时间:2019/12/04
Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial
期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2018, 卷号: 36, 期号: 30
作者:
Xiong, Jianping
;
Qin, Shukui
;
Li, Jin
;
Wang, Liwei
;
Xu, Jianming
收藏
  |  
浏览/下载:6/0
  |  
提交时间:2019/12/05
Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer
期刊论文
INVESTIGATIONAL NEW DRUGS, 2018, 卷号: 36, 期号: 2
作者:
Ouyang, Xuenong
;
Shi, Meiqi
;
Jie, Fangwei
;
Bai, Yuxian
;
Shen, Peng
收藏
  |  
浏览/下载:30/0
  |  
提交时间:2019/12/05
Phase III
Dulanermin
NSCLC
Progression-free survival
Objective response rate
Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial
期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2018, 卷号: 36, 期号: 30
作者:
Qin, Shukui
;
Li, Jin
;
Wang, Liwei
;
Xu, Jianming
;
Cheng, Ying
收藏
  |  
浏览/下载:4/0
  |  
提交时间:2019/12/05
Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial.
期刊论文
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 卷号: 36, 期号: 30, 页码: JCO2018783183
作者:
Qin, Shukui
;
Li, Jin*
;
Wang, Liwei
;
Xu, Jianming
;
Cheng, Ying
收藏
  |  
浏览/下载:9/0
  |  
提交时间:2019/12/03
Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer
期刊论文
INVESTIGATIONAL NEW DRUGS, 2018, 卷号: 36, 期号: 2
作者:
Ouyang, Xuenong
;
Shi, Meiqi
;
Jie, Fangwei
;
Bai, Yuxian
;
Shen, Peng
收藏
  |  
浏览/下载:31/0
  |  
提交时间:2019/12/05
Phase III
Dulanermin
NSCLC
Progression-free survival
Objective response rate
Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer
期刊论文
INVESTIGATIONAL NEW DRUGS, 2018, 卷号: 36, 期号: 2, 页码: 315-322
作者:
Ouyang, Xuenong
;
Shi, Meiqi
;
Jie, Fangwei
;
Bai, Yuxian
;
Shen, Peng
收藏
  |  
浏览/下载:4/0
  |  
提交时间:2019/12/11
Phase III
Dulanermin
NSCLC
Progression-free survival
Objective
response rate
阿帕替尼一线治疗晚期肝细胞癌的前瞻性、随机、开放、全国多中心Ⅱ期临床试验
期刊论文
2017, 卷号: 22, 期号: 12, 页码: 1057-1065
作者:
秦叔逵
;
白玉贤
;
欧阳学农
;
程颖
;
李君
收藏
  |  
浏览/下载:8/0
  |  
提交时间:2020/01/04
肝细胞癌(HCC)
甲磺酸阿帕替尼
Ⅱ期临床试验
©版权所有 ©2017 CSpace - Powered by
CSpace